Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2008-07-22
2008-07-22
Eyler, Yvonne (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C564S005000, C564S363000, C560S220000, C560S250000, C514S649000
Reexamination Certificate
active
07402698
ABSTRACT:
The present invention is directed to secondary amino- and cycloamino-cycloalkanol derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.
REFERENCES:
patent: 3454554 (1969-07-01), Biel et al.
patent: 4221919 (1980-09-01), Grimova et al.
patent: 4229449 (1980-10-01), Melloni et al.
patent: 4310524 (1982-01-01), Wiech et al.
patent: 4535186 (1985-08-01), Husbands et al.
patent: 4826844 (1989-05-01), Husbands et al.
patent: 5502047 (1996-03-01), Kavey
patent: 6703389 (2004-03-01), Wong et al.
patent: 2002/0107249 (2002-08-01), Wong et al.
patent: 2004/0019101 (2004-01-01), Karlstadt et al.
patent: 2004/0143008 (2004-07-01), Deecher et al.
patent: 2004/0152710 (2004-08-01), Deecher et al.
patent: 2004/0180879 (2004-09-01), Deecher et al.
patent: 2556474 (2004-08-01), None
patent: 0 065 757 (1985-01-01), None
patent: 0 208 235 (1990-01-01), None
patent: 0 303 961 (1994-04-01), None
patent: 1 266 659 (2002-12-01), None
patent: WO 91/18602 (1991-12-01), None
patent: WO 97/35586 (1997-10-01), None
patent: WO 99/44601 (1999-09-01), None
patent: WO 00/59851 (2000-10-01), None
patent: WO 01/01973 (2001-01-01), None
patent: WO 02/064543 (2002-08-01), None
patent: WO 02/064543 (2002-08-01), None
patent: WO 02/078691 (2002-10-01), None
patent: WO 03/037334 (2003-05-01), None
patent: WO 03/053426 (2003-07-01), None
patent: WO 03/077897 (2003-09-01), None
patent: WO 2004/016272 (2004-02-01), None
Lecler et al., “Synthesis and Cardiovascular Activity of a New Series f Cyclohexylaralkylamine Derivatives Related t Perhexiline.”, 1982, Journal of Medicinal Chemistry, American Chemical society vol. 25, p. 710.
Bae, J.H. et al., The effects of a selective nonradrenialine reuptake inhibitor on the urethra: an in vitro and in vivo study, 2001, BJU International, vol. 88, issue 7, pp. 771-775.
Deecher, D.C. et al., Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate i overiectomized rodent models, 2006, Endocrinology, vol. 148, No. 3, pp. 1376-1383.
Foley, K. F. et al., Inhibition of transport funciton and disipramine binding at the human noradrenaline transporter by N-ethylmaleimide and protection by substrate analogs, 2002, naunyn-Schmiedeberg's Arch pharmacol, vol. 365 pp. 457-461.
Jackson, J. L. et la., Treatment of functional gastrointestinal disordes with antidepressant medications: a meta-analysis, Experta Medica, Inc., 2002 vol. 108, issue 1, pp. 65-72.
Loprinzi, C. et al., Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial, 2000, The Lancet, vol. 356(9247), 2059-2063.
Quella, S.K. et al., Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing adrogen ablation therapy for prostate cancer, 1999, The Journal of Urology, vol. 162, pp. 98-102.
Schotte, A. et al., Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. 1996, Psychopharmacology, vol. 124, pp. 57-73.
Shin, S. et al., The monoamine reuptake inhibitor milnacipran does not affect nociception to acute visceral distension in rats, 2004, Anesthesia Analg., vol. 98, pp. 1365-1369.
Stearns, V. et al., Hot flashes, Thance Lancet, 2002, vol. 360, pp. 1851-1861.
Walter, M.W., Monoamine reuptake inhibitors: highlights of recent research developments, 2005, Drug Development Research, vol. 65, issue 3, pp. 97-118.
U.S. Appl. No. 60/557,651, filed Mar. 30, 2004, Kim et al.
U.S. Appl. No. 60/557,831, filed Mar. 30, 2004, Kim et al.
U.S. Appl. No. 60/569,863, filed May 11, 2004, Kim et al.
U.S. Appl. No. 60/569,861, filed May 11, 2004, Vu.
U.S. Appl. No. 10/963,458, filed Oct. 12, 2004, Mahaney et al.
U.S. Appl. No. 10/962,881, filed Oct. 12, 2004, Mahaney.
U.S. Appl. No. 10/963,064, filed Oct. 12, 2004, Trybulski et al.
U.S. Appl. No. 10/963,111, filed Oct. 12, 2004, Trybulski et al.
U.S. Appl. No. 10/962,880, filed Oct. 12, 2004, Trybulski et al.
U.S. Appl. No. 10/962,971, filed Oct. 12, 2004, Mahaney et al.
U.S. Appl. No. 10/962,897, filed Oct. 12, 2004, Deecher et al.
Clinical Trial: “Phase III Randomized Study of Medroxyprogesterone Versus Venlafaxine in Women With Symptomatic Hot Flashes”, www.clinicaltrials.gov sponsored by the National Institutes of Health, Study ID Nos. CDR0000069217; NCCTG-N99C7; NCI-P02-0204, 2003, 6 pages.
Acs, N. et al., “Estrogen improves impaired musculocutaneous vascular adrenergic reactivity in pharmacologically ovariectomized rats: a potential peripheral mechanism for hot flashes?”,Endocrinology, 2001 15: 68-73.
Barlow, D. H., “Venlafaxine for hot flushes,”Lancet, Dec. 16, 2000, 356(9247): 2025-2026.
Barton, D. et al., “Hot Flashes—Aetiology and Management,”Drugs and Aging, 2001, 18(8): 597-606.
Berendsen, H. H. G., “Hot Flushes and serotonin,”Journal of the British Menopause Society, Mar. 2002, 8(1): 30-34.
Berendsen, H. H. G., “Effect of tibolone and raloxifene on the tail temperature of oestrogen-deficient rats,”European Journal of Pharmacology, 2001, 419(1): 47-54.
Berendsen, H. H. G., “The role of serotonin in hot flushes,”Maturitas, 2000, 36(3): 155-164.
Bundgaard, H., “Means to enhance penetration; Prodrugs as a means to improve the delivery of peptide drugs,”Advanced Drug Deliver Reviews, 1992, 8, 1-38.
Bundgaard, H. et al., “Glycolamide Esters as Biolabile Prodrugs of Carboxylic Acid Agents: Synthesis, Stability, Bioconversion, and Physicochemical Properties,”J. of Pharmaceutical Sciences, Apr. 1988, 77(4):285-298.
Casper, R. F. et al., “Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism,”Clinical Endocrinology, 1985, 22: 293-312.
Fink, G. et al., “Oestrogen and mental state,”Nature, 1996, 383(6598): 306.
Freedman, R. R. et al., “Clonidine raises the sweating threshold in symptomatic but not asymptomatic postmenopausal women,”Fertility&Sterility, 2000, 74(1): 20-3.
Freedman, R. R., “Physiology of hot flashes,”American Journal of Human Biology, 2001, 13: 453-464.
French, N., “α2-Adrenoceptors and I2sites in the mammalian central nervous system,”Pharmacol. Ther., 1995, 68(2):175-208.
Janowsky, D. S. et al., “Desipramine: an overview,”Journal of Clinical Psychiatry, 1984, 45(10 Pt 2): 3-9.
Katovich, M. J. et al., “Mechanisms Mediating the Thermal Response to Morphine Withdrawal in Rats,”Proceedings of the Society for Experimental Biology&Medicine, 1990, 193(2): 129-35.
Katovich, M. J. et al., “Alpha-adrenergic mediation of the tail skin temperature response to naloxone in morphine-dependent rats,”Brain Research, 1987, 426: 55-61.
Krogsgaard-Larsen, et al., (ed).Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191, 1991.
Kronenberg, F. et al., “Thermoregulatory Physiology of Menopausal Hot Flashes: A Review,”Can. J. Physiol. Pharmacol., 1987, 65:1312-1324.
Loprinzi, C.L. et al., “Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial,”Lancet, Dec. 16, 2000, 356(9247): 2059-2063.
Loprinizi, C. L. et al. “Pilot Evaluation of Venlafaxine Hydrochloride for the Therapy of Hot Flashes in Cancer Survivors,”Journal of Clinical Oncology, Jul. 1998, 16(7): 2377-2381.
Mackinnon et al., “α2-Adrenoceptors: more subtypes but fewer functional differences,&#
Gavrin Lori Krim
Mahaney Paige Erin
Trybulski Eugene John
Webb Michael Byron
Cutliff Yate K
Eyler Yvonne
McKenzie Thomas C.
Wyeth
LandOfFree
Secondary amino-and cycloamino-cycloalkanol derivatives and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Secondary amino-and cycloamino-cycloalkanol derivatives and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Secondary amino-and cycloamino-cycloalkanol derivatives and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2806484